Acadia (ACAD) director Daniel B. Soland resigns, Oct 30, 2025

Acadia Pharmaceuticals Inc. announced that Daniel B. Soland has resigned from its Board of Directors and from his role as Chair of the Nominating and Corporate Governance Committee, effective October 30, 2025.

Rhea-AI Filing Summary

Acadia Pharmaceuticals Inc. announced that Daniel B. Soland has resigned from its Board of Directors and from his role as Chair of the Nominating and Corporate Governance Committee, effective October 30, 2025. The company stated that his resignation was not due to any dispute or disagreement regarding the company’s operations, policies, or practices.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ACAD disclose in this 8-K?

Acadia reported that Daniel B. Soland resigned from the Board and as Chair of the Nominating and Corporate Governance Committee, effective October 30, 2025.

Why did Daniel B. Soland resign from ACAD's board?

The company stated his resignation was not due to any dispute or disagreement regarding operations, policies, or practices.

When is the resignation of Daniel B. Soland effective for ACAD?

His resignation is effective October 30, 2025.

What roles did Daniel B. Soland hold at ACAD?

He served as a Board member and as Chair of the Nominating and Corporate Governance Committee.

What is the trading symbol for Acadia Pharmaceuticals?

Acadia Pharmaceuticals trades on Nasdaq under the symbol ACAD.

Does ACAD cite any disagreements related to the resignation?

No. ACAD states there was no dispute or disagreement with the company or the Board.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/03/2025 - 04:23 PM Learn about SEC filing dates

0001070494false00010704942025-10-282025-10-28

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 28, 2025

Acadia Pharmaceuticals Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			000-50768	06-1376651
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
12830 El Camino Real, Suite 400
San Diego, California				92130
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 558-2871

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		ACAD		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 28, 2025, Daniel B. Soland notified the Board of Directors (the “Board”) of Acadia Pharmaceuticals Inc. (the “Company”) of his resignation from the Board and from his positions as a member and Chair of the Nominating and Corporate Governance Committee of the Board, effective as of October 30, 2025. Mr. Soland’s resignation was not the result of any dispute or disagreement with the Company or the Board on any matter relating to the operations, policies or practices of the Company.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Acadia Pharmaceuticals Inc.
Date:	November 3, 2025	By:	/s/ Jennifer J. Rhodes
			Jennifer J. Rhodes
			Executive Vice President, Chief Legal Officer & Secretary